| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenues | $2.5M+36.2% | $1.9M+45.7% | $1.3M+340.1% | $289K+56.3% | $185K |
| Cost of revenues | $33.3M+27.2% | $26.2M+13.2% | $23.1M+35.5% | $17.1M+15.8% | $14.8M |
| Gross profit | $48.7M+51.3% | $32.2M+33.4% | $24.1M+15.2% | $21.0M+42.4% | $14.7M |
| Selling, general and administrative | $33.0M+31.2% | $25.2M+24.2% | $20.3M+14.6% | $17.7M+18.4% | $15.0M |
| Depreciation and amortization | $8.3M+38.8% | $6.0M+48.9% | $4.0M+38.4% | $2.9M+16.5% | $2.5M |
| Total operating expenses | $41.4M+32.6% | $31.2M+28.3% | $24.3M+17.9% | $20.6M+18.1% | $17.5M |
| Income from operations | $7.4M+620.8% | $1.0M+710.7% | -$167K-148.6% | $344K+112.6% | -$2.7M |
| Interest income, net | $2.7M-14.3% | $3.1M+23.1% | $2.5M+220.0% | $791K+2695.1% | $28K |
| Income before income tax provision | $10.0M+142.5% | $4.1M+75.1% | $2.4M+108.2% | $1.1M+141.9% | -$2.7M |
| Income tax provision | $2.5M+670.0% | $322K+107.9% | -$4.1M-3910.0% | $107K+953.9% | $10K |
| Net income | $7.6M+97.9% | $3.8M-40.9% | $6.5M+528.4% | $1.0M | — |
| Basic | $54.4M+2.3% | $53.2M+1.4% | $52.5M+0.8% | $52.0M+2.1% | $51.0M |
| Diluted | $59.6M+7.3% | $55.6M+2.6% | $54.2M+2.3% | $52.9M+3.8% | $51.0M |
| Plasma Industry [Member] | |||||
| Pharma Industry [Member] | |||||
| Other Revenue [Member] | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.